Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024–2025 season: a target trial emulation study based on registry data
Open Access
- 5 November 2025
- journal article
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 60, 101518
Abstract
No abstract availableKeywords
Funding Information
- European Medicines Agency
This publication has 14 references indexed in Scilit:
- Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre studyInfluenza and Other Respiratory Viruses, 2024
- Target Trial EmulationJAMA, 2022
- Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health recordsBMJ, 2022
- Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designsVaccine, 2022
- Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective – A systematic review of recently published literature on real-world dataVaccine, 2022
- An extended mixed‐effects framework for meta‐analysisStatistics in Medicine, 2019
- Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017Eurosurveillance, 2017
- Vaccines for preventing influenza in healthy adults2010
- Negative ControlsEpidemiology, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007